微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 43.61% | -19.27% | -6.44% | 89/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 46.61% | -15.78% | 2.73% | 84/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 45.37% | -18.9% | -19.05% | 82/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 56.05% | -9.07% | 3.76% | 64/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 54.02% | -10.66% | -2.39% | 69/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 55.34% | -8.38% | -1.08% | 66/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 55.95% | -5.09% | -9.24% | 60/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 61.64% | -2.61% | 1.95% | 48/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 60.46% | -3.74% | 0.09% | 53/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 60.41% | -3.54% | 2.48% | 56/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 58.94% | -5.46% | -6.87% | 54/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 63.29% | 0.78% | 0.77% | 52/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 62.81% | 1.6% | 0.29% | 51/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 62.63% | 2.56% | 0.44% | 52/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 62.35% | 4.93% | -0.72% | 50/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 62.8% | -10.67% | 1.59% | 59/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 61.82% | -19.95% | 1.24% | 51/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 61.06% | -11.95% | 2.76% | 56/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 59.42% | -24.36% | -15.48% | 52/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 70.31% | 120.16% | -8.96% | 37/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 77.23% | 128.28% | 11.35% | 21/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 69.35% | 108.12% | -11.72% | 35/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 78.56% | 144.99% | 146.01% | 19/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 31.93% | -3.11% | -5.6% | 116/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 33.83% | 2.37% | 1.52% | 90/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 33.32% | 6.95% | 3.92% | 96/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 32.07% | 5.69% | -2.71% | 90/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 32.96% | 2.33% | -0.26% | 109/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 33.05% | -0.72% | 6.06% | 84/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 31.16% | -4.27% | 2.69% | 90/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 30.34% | -3.29% | -5.8% | 88/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 32.21% | 0.71% | -3.23% | 92/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 33.28% | 3.35% | 2.26% | 71/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 32.55% | 6.21% | 3.74% | 75/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 31.37% | 6.96% | -1.9% | 62/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 31.98% | 9.39% | -0.7% | 87/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 32.21% | 10.36% | 5.1% | 57/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 30.64% | 7.92% | 4.47% | 69/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 29.33% | 8.56% | 0.33% | 58/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 29.24% | 4.27% | 0.18% | 79/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 29.18% | 4.86% | 2.78% | 57/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 28.39% | 2.91% | 5.09% | 62/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 27.02% | 3.56% | -3.63% | 55/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |